Effects (MACE and bleeding events) of ticagrelor combined with omeprazole on patients with acute myocardial infarction undergoing primary PCI.
This study aimed to investigate the effect of ticagrelor combined with omeprazole on patients with acute myocardial infarction undergoing primary percutaneous coronary intervention (PCI). 86 patients with AMI underwent primary PCI in Xinxiang central hospital between July 2015 and December 2016 were included and divided randomly into observation group and control group by the draw, with 43 patients in each group. All patients were routinely treated with dual antiplatelet therapy with aspirin plus ticagrelor. Omeprazole was used in the observation group and placebo was used in the control group. Baseline data of patients, platelet response index (PRI) ADP-induced platelet aggregation (ADP-Ag), major adverse cardiac events (MACE), and incidence of bleeding events were recorded and compared. PRI and ADP-Ag at 7 days, 1 month, and 6 months after operation in both groups were significantly lower than those in the same group before administration (p<0.017). The follow-up results of hospital referral showed that within 6 months after operation, 5 cases (11.6%) and 3 cases (7.0%) of the observation group and the control group had MACE. There was no significant difference in the incidence of MACE between the two groups (p>0.05). Incidence of bleeding events in the observation group was significantly lower than that in the control group (p<0.05). For AMI patients undergoing primary PCI, omeprazole can reduce the incidence of gastrointestinal bleeding without reducing the antiplatelet aggregation effect of ticagrelor or increasing the risk of MACE, which is worthy of clinical promotion.